Skip to main content
Blood in Vial in Lab)


Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.

Product Information

  • Hemophilia A – Treatment and prevention of bleeding in adults.
  • Von Willebrand disease (VWD) – in adults and pediatric patients in the 
    • (1) Treatment of spontaneous and trauma-induced bleeding episodes, and
    • (2) Prevention of excessive bleeding during and after surgery.

This applies to patients with severe VWD as well as patients with mild to moderate VWD where the use of desmopressin is known or suspected to be inadequate. HUMATE-P is not indicated for the prophylaxis of spontaneous bleeding episodes in VWD.

Anaphylactic or severe systemic reaction to antihemophilic factor or VWF preparations.

Hemophilia A 

  • One International Unit (IU) of factor VIII (FVIII) activity per kg body weight increases the circulating FVIII level by approximately 2.0 IU/dL. Individualize dosage based on the patient’s weight, type and severity of hemorrhage, FVIII level, and presence of inhibitors (2.1). 


  • Treatment of bleeding episodes – 40-80 IU VWF:Ristocetin Cofactor (RCo) per kg body weight (BW) every 8-12 hours.
  • Prevention of excessive bleeding during and after surgery for all types of VWD
Type of Surgery
(see Full Prescribing Information
for monitoring recommendations)
Calculation of Loading Dose 
Initial maintenance dose should be half the loading dose
(see Full Prescribing Information for monitoring recommendations)
Major Surgery (2,3) Δ * VWF:RCo x BW (kg)  = IU VWF:RCo required
Minor/Oral Surgery (2,3) Δ * VWF:RCo x BW (kg)  = IU VWF:RCo required 
Emergency Surgery (2,3) Administer a dose of 50-60 IU VWF:RCo/kg BW

*   Δ = Target peak plasma VWF:RCo level - baseline plasma VWF:RCo level.
†  IVR = in vivo recovery as measured in the patient. If the IVR is unknown, use 2.0 IU/dL per IU/kg
‡  Oral surgery is defined as extraction of fewer than three teeth, if the teeth are non-molars and have no bony involvement

  • HUMATE-P is for intravenous use only.
  • HUMATE-P is available as a lyophilized powder in single-dose vials that contain the labeled amount of VWF:RCo and FVIII activity expressed in IU. The average ratio of VWF:RCo to FVIII is 2.4:1. 
  • Do not refrigerate HUMATE-P after reconstitution. Administer within 3 hours after reconstitution. 
  • Slowly infuse the solution (maximally 4 mL/minute) with a suitable intravenous administration set. 
For U.S. Healthcare Professionals only
For U.S. Healthcare Professionals only

The purpose of this CSL Behring Medical Affairs website is to support Healthcare Professionals with scientific information. This website is also a channel for U.S. Healthcare Professionals to submit questions or connect with CSL Behring U.S. Healthcare Professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US Healthcare Professional

toggle chat overlay
toggle chat overlay